Classical Hodgkin's lymphoma (cHL) is a rather rare disease with an incidence of 2-3/100,000 per year and typically presents in patients at the age of 20-30. lt is however well known that a second peak occurs at the age of 60-65 years.1 Nowadays Hodgkin is a curable disease for most of the younger patients but treatment is more difficult and less successful in the aider patient population. ln this review, we want to summarise the possibilities for the treatment of cHL patients above 60 years, with a focus on evidence from the raher rarely available clinical trials. We also look at future treatments . ln this article we will use the term 'aider.patients' for patients of 60 years and older at diagnosis. We will make a distinction between fit patients older than 60 years and frail or vulnerable patients (so called elderly).